Cargando…

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms

INTRODUCTION: The aim was to create readily available algorithms that estimate the individual risk of β-amyloid (Aβ) positivity. METHODS: The algorithms were tested in BioFINDER (n = 391, subjective cognitive decline or mild cognitive impairment) and validated in Alzheimer's Disease Neuroimagin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palmqvist, Sebastian, Insel, Philip S., Zetterberg, Henrik, Blennow, Kaj, Brix, Britta, Stomrud, Erik, Mattsson, Niklas, Hansson, Oskar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier, Inc 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374284/ https://www.ncbi.nlm.nih.gov/pubmed/30365928 http://dx.doi.org/10.1016/j.jalz.2018.08.014

Ejemplares similares

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2018)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis
por: Mattsson, Niklas, et al.
Publicado: (2016)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
por: Palmqvist, Sebastian, et al.
Publicado: (2017)

β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly
por: Svenningsson, Anna L., et al.
Publicado: (2019)

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2020)

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
por: Pereira, Joana B., et al.
Publicado: (2022)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
por: Kumar, Atul, et al.
Publicado: (2022)

Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes
por: Cicognola, Claudia, et al.
Publicado: (2023)

Plasma β-amyloid in Alzheimer’s disease and vascular disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Comparing progression biomarkers in clinical trials of early Alzheimer’s disease
por: Cullen, Nicholas C., et al.
Publicado: (2020)

Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2018)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease
por: Cullen, Nicholas C, et al.
Publicado: (2023)

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials
por: Borland, Emma, et al.
Publicado: (2022)

Plasma tau in Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition
por: Tideman, Pontus, et al.
Publicado: (2022)

Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET
por: van Westen, Danielle, et al.
Publicado: (2016)

Towards a unified protocol for handling of CSF before β-amyloid measurements
por: Janelidze, Shorena, et al.
Publicado: (2019)

Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease
por: Buchhave, Peder, et al.
Publicado: (2009)

Genetic Moderation of the Association of β-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease
por: Insel, Philip S., et al.
Publicado: (2023)

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
por: Cicognola, Claudia, et al.
Publicado: (2021)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid, tau, and cognition
por: Cullen, Nicholas C., et al.
Publicado: (2021)

Association of CSF Aβ(38) Levels With Risk of Alzheimer Disease–Related Decline
por: Cullen, Nicholas, et al.
Publicado: (2022)

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2021)

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease
por: Stomrud, Erik, et al.
Publicado: (2010)

Determining clinically meaningful decline in preclinical Alzheimer disease
por: Insel, Philip S., et al.
Publicado: (2019)

Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease
por: Kumar, Atul, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tqfhdbi0n4vn32hskfd43jgdsm